Skip to content
Back to Blog
Bio
2026-10-267 min read5

From Approval to Hospital in as Few as 80 Days Without New Health Technology Assessment — Nine Months into Korea's 'Market Immediate Entry Medical Technology' Track: How SME Medical Device Makers of AI Software, IVD Reagents and Surgical Robots Can Check Eligibility Among 199 Items and Prepare for Enhanced Clinical Evaluation and Post-Entry Reassessment (2026)

Since January 2026, 199 items including AI medical software, IVD reagents and surgical robots can reach Korean hospitals in as few as 80 days without a separate New Health Technology Assessment. This guide lays out the steps for SME device makers, from checking eligibility to strengthening approval-stage clinical evidence, preparing for reassessment and securing sales channels.

KITIM Consulting Team

From 490 Days to Market — What Has Changed

Until recently, a new medical device in Korea had to clear four stages before hospitals could use it: MFDS approval → confirmation of whether it is an existing technology → New Health Technology Assessment (nHTA) → National Health Insurance listing. Reviews and waiting times stacked up, so a company could wait up to 490 days after approval, with capital and staff tied up the whole time. For SMEs, that gap was often the hardest part to survive.

An amendment to the Rules on New Health Technology Assessment, in force since January 26, 2026, cuts this path to two stages at most for eligible items. They can reach clinical practice in as few as 80 days (typically 80–140 days) after approval. The track does not remove scrutiny, though. It moves what nHTA used to examine forward into an "enhanced clinical evaluation at an international standard" at the approval stage. The Ministry of Health and Welfare and the MFDS run the track jointly, and it only works if the company brings strong evidence at approval.

Check Eligibility First — The 199-Item List

The MFDS has announced 199 eligible items:

  • 113 digital medical devices, centered on AI products such as imaging detection and diagnostic-assist software
  • 83 in vitro diagnostic (IVD) reagents
  • 3 medical robots
  • Eligibility depends on product classification (item name and class), not on how innovative the technology is. Confirming your exact classification code is therefore the first step. Items that are not on the list still follow the existing nHTA or deferred-assessment routes. A wrong classification can derail an entire development plan, so it is worth confirming early through an MFDS classification consultation.

    The Price of Immediate Entry — Heavier Clinical Design at Approval

    The biggest change falls on approval-stage clinical studies. The standard for comparators, endpoints and efficacy evidence now effectively matches nHTA.

  • In exploratory studies, look beyond performance and set hypotheses about which clinical decisions your product actually changes in real care pathways
  • In confirmatory studies, design the trial to capture clinical utility evidence against standard care
  • Because costs and timelines grow, aligning your schedule with government R&D and clinical trial support programs, such as the Korea Medical Device Development Fund, helps share the burden
  • The Real Test Comes After Entry — Use Period and Reassessment

    Technologies that enter through this track are reassessed after a set period of clinical use. Check the exact period and requirements against the official notices and announcements. Weak evidence at reassessment can make continued use difficult, so plan the following before entry:

  • A real-world data (RWD) plan: what to collect, for how long, and how to analyze it
  • Hospital partnerships: participating sites, data-linkage methods and IRB procedures
  • A pricing and reimbursement roadmap: how to price and sell to hospitals if you enter as a non-covered service, and a timeline toward insurance listing
  • Nine Months In — What the Field Shows

    Companies on the same track are seeing different results. The gap usually comes down to three factors: whether the item is on the list, whether the approval-stage evidence is strong enough, and whether hospitals actually want to adopt it.

    It is easy to miss that market entry and reimbursement or sales channels are separate problems. Faster entry does not become revenue unless hospitals have a clear reason to use the product and a workable cost structure. Without a sales strategy, the time saved has limited value.

    Action Checklist for SME Device Makers

  • Confirm classification and eligibility: match your classification code against the 199-item list
  • Revisit approval-stage clinical design: strengthen comparators, endpoints and clinical-utility evidence
  • Plan data for reassessment: build RWD collection and secure partner hospitals
  • Set reimbursement and sales strategy: non-covered pricing, hospital sales and a listing roadmap
  • Making full use of MFDS pre-submission consultations and product commercialization support programs can save a great deal of trial and error along the way.

    KITIM helps medical device companies build regulatory roadmaps, design clinical strategies and connect with government R&D and clinical support programs. If you are unsure whether your product qualifies for immediate entry or how to strengthen your approval-stage evidence, contact KITIM. We will work with you on a market-entry strategy that fits your product's stage.

    Market Immediate Entry Medical TechnologyNew Health Technology AssessmentInnovative Medical DevicesAI Medical DevicesIn Vitro DiagnosticsMedical Device ApprovalHealth Insurance ListingSME Medical Device Companies

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.